Slingshot members are tracking this event:

Merck Completes Enrollment in Pivotal Phase 3 “EPOCH” Trial Investigating the Efficacy and Safety of Verubecestat in Patients with Mild-to-Moderate Alzheimer’s Disease; primary trial completion expected in July 2017.

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks
MRK Community voting in process

Additional Information

Additional Relevant Details The ongoing EPOCH study is designed to evaluate the safety and efficacy of two oral doses of verubecestat (12 mg and 40 mg) administered once daily versus placebo in patients with mild-to-moderate AD currently using standard of care treatment. The primary efficacy outcomes of the study are the change from baseline in the Alzheimer's Disease Assessment Scale Cognitive Subscale (ADAS-Cog) score, as well as the change from baseline in the Alzheimer's Disease Cooperative Study – Activities of Daily Living (ADCS-ADL) score, following 78 weeks of treatment. Merck is also investigating the safety and efficacy of verubecestat in the earlier, prodromal phase of AD in an additional Phase 3 clinical trial called APECS.
Additional Relevant Details This study has been terminated
Slingshot Insights Explained
Catalyst Date
Occurred on:
Apr 27, 2017
Occurred Source:
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Complete Enrollment, Pivotal Phase 3 Trial, Epoch Trial, Verubecestat, Alzheimer, Oral Small Molecule Selective Beta Secretase